The tyrosine kinase inhibitor imatinib mesylate (Gleevec)(formerly STI571) has proven to be
an effective and safe new therapy for patients with chronic myeloid leukemia (CML). It has …

Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …

The role of molecular monitoring for patients with chronic myeloid leukemia (CML) is
multifaceted. Milestone measurements up to 18 months of first-line imatinib therapy are …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …

The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …

The results of imatinib (Gleevec)(formerly STI571) therapy for chronic myeloid leukemia
(CML) have continued to improve and have surpassed almost everyone's predictions …

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a
specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene …

The Bcr-Abl tyrosine kinase inhibitor imatinib (Glivec®, formerly STI571, Novartis Pharma
AG, Basel, Switzerland) produces complete hematologic and cytogenetic responses in a …

Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …

Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …